A prospective evaluation of the tolerability and safety of Stalevo™ (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off

被引：0

|

作者：

Koller, W

Silver, D

Guarnieri, M

Hubble, J

Rabinowicz, A

机构：

来源：

MOVEMENT DISORDERS | 2004年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P577

引用

收藏

页码：S205 / S206

页数：2

相关论文

共 50 条

[31] A randomized, double-blind evaluation of levodopa/carbidopa/entacapone versus immediate-release levodopa/carbidopa in patients with Parkinson's disease exhibiting nonmotor symptoms of wearing off
Stacy, M.
Mccague, K.
Weidenman, M.
Campbell, A.
Somogyi, M.
[J]. PARKINSONISM & RELATED DISORDERS, 2009, 15 : S113 - S114
[32] Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations.: A randomized, double-blind, multicentre study
Fénelon, G
Giménez-Roldán, S
Montastruc, JL
Bermejo, F
Durif, F
Bourdeix, I
Péré, JJ
Galiano, L
Schadrack, J
[J]. JOURNAL OF NEURAL TRANSMISSION, 2003, 110 (03) : 239 - 251
[33] Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa:: a randomized, crossover, multicentre study in patients with Parkinson's disease
Marttila, R.
Kaasinen, V.
Hartikainen, P.
Lyytinen, J.
Kaakkola, S.
Hanninen, J.
Korpela, K.
Laapas, K.
Kuoppamaki, M.
Ellmen, J.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 115 - 115
[34] Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa:: a randomized, crossover, multicentre study in patients with Parkinson's disease
Kaakola, S.
Ellmen, J.
Marttila, R.
Kaasinen, V.
Hartikainen, P.
Lyytinen, J.
Hanninen, J.
Korpela, K.
Kuoppamaki, M.
[J]. PARKINSONISM & RELATED DISORDERS, 2007, 13 : S100 - S100
[35] Improvement of everyday activity of Parkinson-patients with treatment with Stalevo (Levodopa/Carbidopa/Entacapone)
Muller, Thomas
Roscher, T.
Mehl, C.
[J]. AKTUELLE NEUROLOGIE, 2007, 34 (08) : A4 - A11
[36] Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa:: A randomized, crossover, multicenter study in patients with Parkinson's disease
Marttila, R.
Kaasinen, V.
Hartikainen, P.
Lyytinen, J.
Kaakkola, S.
Haenninen, J.
Korpela, K.
Laapas, K.
Kuoppamaeki, M.
Ellmen, J.
[J]. MOVEMENT DISORDERS, 2008, 23 (01) : S213 - S213
[37] Levodopa/carbidopa/entacapone in early Parkinson's disease
[J]. Reactions Weekly, 2020, 1798 (1) : 10 - 10
[38] Real-world considerations regarding the use of the combination of levodopa, carbidopa, and entacapone (Stalevo®) in Parkinson's disease
Reichmann, Heinz
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 15 - 20
[39] Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)
Solla, Paolo
Cannas, Antonino
Marrosu, Francesco
Marrosu, Maria Giovanna
[J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 483 - 490
[40] New levodopa/carbidopa/entacapone (Stalevo®) results in better quality of life for Parkinson's disease patients and saves costs to the society
Findley, L
Turunen, H
Apajasalo, M
Lees, A
[J]. VALUE IN HEALTH, 2004, 7 (06) : 788 - 788

← 1 2 3 4 5 →